Oregon-based bioscience startup to be featured at Life Science Innovation Northwest 2014, June 19-20 in Seattle
PORTLAND, Ore. – AbSci, LLC (http://www.abscibio.com), a life science technologies company located at the OTRADI Bioscience Incubator (OBI) in Portland, is headed to Seattle, Washington next month to present its novel proprietary expression system at Life Science Innovation Northwest, aconference expected to draw hundreds of innovators in biopharma, medical technology, research, global health, digital health, biofuels and veterinary medicine.
AbSci CEO Sean McClain will detail the company’s core technology, SoluPro™, for conference goers. “What we have created is a bioengineered E. coli expression system that allows the scalable production of soluble, functional recombinant antibodies, enzymes and other proteins without altering their characteristics,” McClain said.
The SoluPro technology already has generated interest among pharmaceutical manufacturers due to its capacity to increase overall process yield 25 to 50 fold and decrease drug production time by 50 to 90 percent. According to McClain, this is accomplished by eliminating inclusion body formation, and by using high-throughput methods of optimization. For the biofuels industry, SoluPro offers the potential to use second-generation feedstocks known as lignocellulosic biomass to cost effectively produce alternatives to fossil fuels.
In April the AbSci team exhibited SoluPro for pharmaceutical, biopharmaceutical and biotechnology companies at a Proteins and Antibodies Congress in London, England. This event was one in a series of milestones for AbSci, which has tripled its workforce since locating at OBI in June 2013.
Life Science Innovation Northwest, 2014 is sponsored by the Washington Biotechnology and Biomedical Association. It is billed as “North America’s largest, fully-integrated life science exposition.”
Established in 2011, AbSci is committed to enhancing global health by reducing biotherapeutic costs and advancing clean energy technologies. As part of this aim, AbSci developed SoluPro™, a bioengineered E. coli expression system that expedites the drug discovery process while reducing production time and cost, and allows the scalable production of soluble recombinant antibodies, enzymes and other proteins without altering their characteristics. AbSci is headquartered at the OTRADI Bioscience Incubator in Portland, Ore., one of the United States’ fastest growing bioscience clusters. http://www.abscibio.com